Objective
to determine whether early aspirin withdrawal (within 4 days after PCI) and continuation of potent P2Y12 inhibitor monotherapy is non-inferior to standard 12-month DAPT for ischaemic events and superior for bleeding prevention in patients with ACS
Study
multicentre, open-label, randomised controlled trial
Population
patients with ACS who underwent successful PCI with DES
Endpoints
composite of all causes of death, myocardial infarction, stroke or urgent target-vessel revascularisation; major or clinically relevant non-major bleeding
Conclusion
In patients with successful PCI for ACS, potent P2Y12 inhibitor monotherapy was not non-inferior to DAPT in terms of a composite of death or ischaemic events at 12 months.
Guimarães et al. NEJM. 2025 Aug 31.